Global drugmakers invest billions to boost U.S. presence
Global drugmakers plan major U.S. manufacturing and R&D expansions, citing supply-chain resilience and tariff risk. The article says companies including Pfizer, GSK, Eli Lilly, J&J, Roche, AstraZeneca, Novartis, Sanofi, Biogen, Merck, Amgen, AbbVie, Gilead, Bristol Myers Squibb, Cipla, and CSL have pledged about US$500 billion. Examples include Pfizer’s US$70B, Lilly’s US$27B-plus, and Merck’s US$70B-plus.





